Log in to your Inderes Free account to see all free content on this page.
Elicera Therapeutics
5.44 SEK
0.00 %
Less than 1K followers
ELIC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
0.00 %
-11.83 %
+4.21 %
+4.21 %
-22.73 %
+78.95 %
+49.86 %
-
-12.26 %
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.
Read moreMarket cap
264.03M SEK
Turnover
158.85K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5.5.
2026
General meeting '26
5.5.
2026
Interim report Q1'26
21.8.
2026
Interim report Q2'26
All
Research
Press releases
3rd party
ShowingAll content types
DNB Carnegie Access: Elicera Therapeutics: Focused on the future of immuno-oncology
Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio